A treatment that blocks an age-related protein restored cartilage in aging and injured joints by reprogramming existing cells ...
Background OnabotulinumtoxinA has demonstrated significant benefit in adult focal spasticity. This study reviews the injection patterns (i.e., muscle distribution, dosing) of onabotulinumtoxinA for ...
Chronic muscle tension is a common underlying factor in many pain disorders, causing reduced arterial blood flow, tissue hypoxia, and the release of inflammatory mediators. These physiological changes ...
June 20 (Reuters) - The U.S. Food and Drug Administration has approved Argenx SE's ARGX.BR under-the-skin injection for the treatment of a muscle-weakening genetic diseasecalled generalized myasthenia ...
Scientists at Stanford Medicine have reported a discovery that could change how arthritis and joint damage are treated. In experiments on animals and human tissue, researchers found that blocking a ...
Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback